AVITA Medical, Inc. (RCEL)
NASDAQ: RCEL · Real-Time Price · USD
3.790
-0.050 (-1.30%)
Nov 21, 2025, 4:00 PM EST - Market closed
AVITA Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Jun '21 Jun 30, 2021 | 2016 - 2020 |
| 72.4 | 64.25 | 50.14 | 34.42 | 33.03 | 29.23 | Upgrade | |
Revenue Growth (YoY) | 20.59% | 28.14% | 45.68% | 4.23% | 12.98% | 104.95% | Upgrade |
Cost of Revenue | 11.77 | 9.09 | 7.78 | 6.04 | 6.1 | 5.95 | Upgrade |
Gross Profit | 60.63 | 55.16 | 42.36 | 28.38 | 26.92 | 23.28 | Upgrade |
Selling, General & Admin | 82.72 | 91.39 | 65.63 | 45.24 | 37.92 | 37.06 | Upgrade |
Research & Development | 20 | 20.36 | 20.82 | 13.86 | 15.67 | 14.82 | Upgrade |
Other Operating Expenses | - | - | -1.43 | -3.22 | -1.59 | -2.06 | Upgrade |
Operating Expenses | 102.71 | 111.75 | 85.02 | 55.89 | 52 | 49.82 | Upgrade |
Operating Income | -42.08 | -56.59 | -42.66 | -27.51 | -25.08 | -26.54 | Upgrade |
Interest Expense | -214.05 | -211.36 | -776.14 | -0.02 | -0.03 | -0.02 | Upgrade |
Interest & Investment Income | 1.1 | 2.7 | 3.1 | - | - | - | Upgrade |
Currency Exchange Gain (Loss) | -0.02 | -0.02 | -0.02 | - | - | - | Upgrade |
Other Non Operating Income (Expenses) | 207.25 | 205.98 | 773.8 | 0.89 | 0.05 | 0.02 | Upgrade |
EBT Excluding Unusual Items | -47.81 | -59.29 | -41.92 | -26.63 | -25.06 | -26.55 | Upgrade |
Gain (Loss) on Sale of Assets | - | - | 9.4 | - | - | - | Upgrade |
Asset Writedown | - | - | - | - | -0.04 | - | Upgrade |
Other Unusual Items | -0.7 | -2.5 | -2.8 | - | - | - | Upgrade |
Pretax Income | -48.51 | -61.79 | -35.32 | -26.63 | -25.1 | -26.55 | Upgrade |
Income Tax Expense | 0.05 | 0.05 | 0.07 | 0.04 | 0.04 | 0.04 | Upgrade |
Earnings From Continuing Operations | -48.56 | -61.85 | -35.38 | -26.67 | -25.14 | -26.58 | Upgrade |
Net Income | -48.56 | -61.85 | -35.38 | -26.67 | -25.14 | -26.58 | Upgrade |
Net Income to Common | -48.56 | -61.85 | -35.38 | -26.67 | -25.14 | -26.58 | Upgrade |
Shares Outstanding (Basic) | 27 | 26 | 25 | 25 | 24 | 23 | Upgrade |
Shares Outstanding (Diluted) | 27 | 26 | 25 | 25 | 24 | 23 | Upgrade |
Shares Change (YoY) | 4.20% | 2.18% | 1.32% | 2.64% | 7.42% | 11.75% | Upgrade |
EPS (Basic) | -1.81 | -2.39 | -1.40 | -1.07 | -1.03 | -1.17 | Upgrade |
EPS (Diluted) | -1.81 | -2.39 | -1.40 | -1.07 | -1.03 | -1.17 | Upgrade |
Free Cash Flow | -37.13 | -58.11 | -39.39 | -19.54 | -18.52 | -26.8 | Upgrade |
Free Cash Flow Per Share | -1.39 | -2.25 | -1.55 | -0.78 | -0.76 | -1.18 | Upgrade |
Gross Margin | 83.74% | 85.85% | 84.48% | 82.45% | 81.52% | 79.65% | Upgrade |
Operating Margin | -58.13% | -88.08% | -85.07% | -79.91% | -75.93% | -90.79% | Upgrade |
Profit Margin | -67.06% | -96.25% | -70.56% | -77.47% | -76.13% | -90.94% | Upgrade |
Free Cash Flow Margin | -51.28% | -90.44% | -78.56% | -56.77% | -56.09% | -91.66% | Upgrade |
EBITDA | -40.03 | -55.47 | -42.02 | -26.94 | -24.4 | -25.83 | Upgrade |
EBITDA Margin | -55.28% | -86.33% | -83.81% | -78.26% | -73.89% | -88.34% | Upgrade |
D&A For EBITDA | 2.06 | 1.13 | 0.63 | 0.57 | 0.67 | 0.72 | Upgrade |
EBIT | -42.08 | -56.59 | -42.66 | -27.51 | -25.08 | -26.54 | Upgrade |
EBIT Margin | -58.13% | -88.08% | -85.07% | -79.91% | -75.93% | -90.79% | Upgrade |
Revenue as Reported | 72.4 | 64.25 | 50.14 | - | - | - | Upgrade |
Advertising Expenses | - | 0.54 | 0.4 | 0.22 | - | 0.07 | Upgrade |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.